For many years, economists, regulators, and public health researchers have used a dollar figure that has been quietly at the heart of American environmental regulation to address an almost uncomfortable question: how much is a human life worth? For many years, the EPA’s response was roughly $11.7 million per person. This amount came from wage-risk studies and labor market research, and it was eventually refined into what is known as the Value of Statistical Life. It wasn’t flawless. In economics, nothing is. However, it served as a means of bringing the invisible to light, transforming death prevention into a figure that could be recorded alongside industry compliance expenses on a cost-benefit ledger.
The EPA eliminated that figure on January 8, 2026. swapped it out for nothing. Nothing. The agency declared that when assessing air pollution regulations pertaining to ozone and fine particulate matter, the economic value of lives saved would no longer be taken into account. Industry-specific compliance costs are still fully recorded, meticulously totaled, and weighted. The prevented hospital stays, prevented asthma attacks, and prevented deaths are now recorded as $0 in the official computation. It’s difficult to look at that without experiencing something akin to disbelief.
| Category | Details |
|---|---|
| Agency | U.S. Environmental Protection Agency (EPA) |
| Key Policy Change | Elimination of the “Value of Statistical Life” (VSL) from regulatory cost-benefit analyses for air pollution rules |
| Previous VSL Figure | Approximately $11.7 million per person — used to calculate benefits of lives saved by pollution regulations |
| New VSL Figure | $0.00 — health benefits of lives saved and illnesses avoided no longer counted |
| Date of Change | January 8, 2026 |
| Affected Regulations | Rules governing fine particulate matter (PM2.5) and ozone pollution — linked to asthma, hospitalizations, and premature death |
| EPA’s Stated Rationale | Quantifying health benefits deemed “too uncertain”; industry compliance costs remain fully counted |
| Estimated Annual Deaths | Approximately 11,000 deaths prevented annually by mercury and air pollution rules now counted as $0 in benefit |
| Key Critic | Andrew Behar, CEO of As You Sow — leading shareholder advocacy non-profit |
| Academic Voice | Michael Greenstone, environmental economist, University of Chicago — warns of dirtier air and reversal of Clean Air Act gains |
| Clean Air Act Impact | The 1970 law, strengthened by Congress, added an estimated 1.4 years to average American life expectancy |
| Broader Context | Change preceded EPA’s move to revoke the Endangerment Finding — the legal foundation for regulating greenhouse gases |
As You Sow CEO and longtime shareholder advocate Andrew Behar wrote about the ruling in Fortune at the beginning of April, characterizing it not only as a moral failure but also as something more structurally concerning: a market failure. His argument merits greater consideration than it currently receives. He noted that the government does not establish neutrality when it eliminates human life from the ledger. It manipulates the formula. The advantages of cleaner air don’t formally exist, and pollution is suddenly inexpensive on paper. In the most straightforward regulatory language imaginable, the federal government has just informed anyone attempting to make a logical investment decision in public health technology, pharmaceutical development, or healthcare infrastructure that the results of their labor are worthless.
Environmental economist Michael Greenstone of the University of Chicago stated it simply and without fanfare. Since Congress strengthened the Clean Air Act in 1970, the average American’s life expectancy has increased by about 1.4 years. In contemporary American history, that is among the most quantifiable and verifiable returns on any government investment. Greenstone stated, “Clean air is one of the great success stories of government policy in the last half-century,” pointing out that the framework as a whole is predicated on the notion that longer, healthier lives have quantifiable financial value. You haven’t improved the analysis’s objectivity by eliminating that measurement. Simply put, you’ve made it simpler to defend doing less.
According to the EPA, measuring health benefits adds too much uncertainty to the regulatory process. There is a superficial logic to that; economists disagree on methodology, and VSL estimates do involve assumptions. However, it’s also important to observe what this framework ignores. Costs associated with industry compliance, which are based on their own projections and assumptions, are still included in the computation. It appears that there is only one direction of uncertainty. It is at this asymmetry that ideology begins to resemble accounting.
The full effects of this change might not be felt right away. Writing, challenging, and implementing regulations takes time. However, compared to regulatory timelines, the downstream effects on investment decisions are less patient. Institutional investors conducting ESG risk assessments, insurers modeling long-term liability, and environmental health companies all employ some form of VSL logic in their frameworks. The federal government sends a signal to anyone attempting to price risk, not just activists, when it sets that value to zero. It informs them that the government no longer plans to act as a buffer against environmental damage, which alters the calculations for everything from municipal bond ratings in highly polluted areas to air filtration startups.
Behar brought up a larger absurdity that is worth pondering for a while. In a very literal sense, human activity—people working, spending, building, and consuming—is the foundation of the entire American economy. Bad air quality is not the logical conclusion if the official regulatory stance is that human life has no quantifiable economic value. It undermines the basis of the economy itself. Hospitals are necessary because sickness is expensive. Because life has value, there are markets for life insurance. Because investors think that keeping people alive yields returns, pharmaceutical companies are able to attract capital. Environmental regulation is not the only thing a $0 VSL does. It compromises market logic’s internal coherence.
As this develops, what’s remarkable isn’t the noise it created—op-eds, scholarly opposition, shareholder advocates raising concerns—but rather the lack of structural opposition it encountered in the months since January. The change to the rule was subtle, technical, and buried in regulatory jargon. Until opinion writers began doing the math aloud, the majority of people outside of environmental law circles were unaware. The problem with deleting a number from a spreadsheet is that. It doesn’t appear to be a disaster. However, the math is already being done in hospital rooms somewhere, in a neighborhood where kids carry inhalers to school, in a county downwind of an industrial facility.
